PI3Kδ/γ Inhibitor Duvelisib Modulates Inflammatory Profile in Severe COVID-19 Patients: Results from a Randomized Placebo-Controlled Phase 2 Study

被引：0

作者：

Zhang, Hanwen ^{[1
]}

Wang, Shuhua ^{[1
]}

Rupji, Manali ^{[2
]}

Wu, Chenxi ^{[3
]}

Chandrasekaran, Sanjay ^{[4
]}

Funk, Christopher R. ^{[1
]}

King, Patrick J. ^{[5
]}

Kollipara, Saketh ^{[6
]}

Rao, Ishani ^{[6
]}

Ayanru, Esohe ^{[6
]}

Duffy, Julia ^{[7
]}

Kaplow, Roberta ^{[7
]}

Abousaud, Aseala ^{[8
]}

Mehta, Aneesh ^{[9
]}

Roback, John D. ^{[5
]}

Kalman, Daniel ^{[5
]}

Lyon, G. Marshall, III ^{[9
]}

Caridi-Scheible, Mark ^{[10
]}

Bisson, Gregory ^{[11
]}

Liu, Yuan ^{[2
]}

Coma, Silvia ^{[12
]}

Pachter, Jonathan A. ^{[12
]}

Giver, Cynthia R. ^{[1
]}

Waller, Edmund K. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[2] Emory Univ, Winship Canc Inst, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA

[3] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA

[4] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[5] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA

[6] Emory Univ, Atlanta, GA 30322 USA

[7] Emory Univ Hosp, Emory Healthcare, 1364 Clifton Rd NE, Atlanta, GA 30322 USA

[8] Emory Healthcare, Atlanta, GA USA

[9] Emory Univ, Sch Med, Dept Infect Dis, Atlanta, GA 30322 USA

[10] Emory Univ, Sch Med, Crit Care Med, Atlanta, GA 30322 USA

[11] Univ Penn, Perelman Sch Med, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA

[12] Verastem Oncol, Needham, MA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165567

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：11187 / 11189

页数：3

共 50 条

[31] Homoeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study
Kaur, Harleen
Kaushik, Subhash
Singh, Gurpreet
Kumar, Arvind
Singh, Shweta
Chatterjee, Tania
Ali, Syed
Gautam, Khushbu
Parewa, Maneet
Verma, Naval Kumar
Bhatnagar, Sushma
Singh, Suraj Pal
Shekhar, Varun
Khurana, Anil
HOMEOPATHY, 2023, 112 (03) : 184 - 197
[32] A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
Ferrannini, E.
Seman, L.
Seewaldt-Becker, E.
Hantel, S.
Pinnetti, S.
Woerle, H. J.
DIABETES OBESITY & METABOLISM, 2013, 15 (08): : 721 - 728
[33] Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19 A Phase 2 Randomized Clinical Trial
Cafardi, John
Miller, Carole
Terebelo, Howard
Tewell, Chad
Benzaquen, Sadia
Park, David
Egan, Pamela
Lebovic, Daniel
Pettit, Kristen
Whitman, Eric
Tremblay, Douglas
Feld, Jonathan
Buckley, Sarah
Roman-Torres, Karisse
Smith, Jennifer
Craig, Adam
Mascarenhas, John
JAMA NETWORK OPEN, 2022, 5 (12) : e2242918
[34] Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients
de Souza, Savio Bastos
Cabral, Paula Gebe Abreu
da Silva, Renato Martins
Arruda, Raul Ferraz
Cabral, Sheila Passos de Figueiredo
de Assis, Aricia Leone Evangelista Monteiro
Viana Junior, Antonio Brazil
Degrave, Wim Maurits Sylvain
Moreira, Aline dos Santos
Silva, Cleber Gloria
Chang, Junbiao
Lei, Pingsheng
FRONTIERS IN MEDICINE, 2023, 10
[35] Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
Deodhar, Atul
Supronik, Jerzy
Kivitz, Alan
Valenzuela, Guillermo
Kapur, Karen
Rohrer, Susanne
Dokoupilova, Eva
Richards, Hanno B.
Pavelka, Karel
ARTHRITIS & RHEUMATOLOGY, 2024,
[36] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (PALACE 1, 2, AND 3)
Bird, P.
Blanco, F.
Kavanaugh, A.
Adebajo, A.
Edwards, C.
Crowley, J.
Stevens, R.
Hu, C.
Mease, P.
INTERNAL MEDICINE JOURNAL, 2014, 44 : 19 - 19
[37] Efficacy and safety of adalimumab in Chinese patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, placebo-controlled, double-blind Study
Zhang, Jianzhong
Gu, Jun
Zheng, Jie
Zheng, Min
Wang, Gang
Gu, Yihua
Okun, Martin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB232 - AB232
[38] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Susan
Zhou, Feng
Assad, Albert
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[39] A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naive myelofibrosis
Yacoub, Abdulraheem
Erickson-Viitanen, Sue
Zhou, Feng
Assad, Albert
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 115 - 116
[40] Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma
Dreyling, Martin
Cunningham, David
Bouabdallah, Krimo
Assouline, Sarit
Van den Neste, Eric
Vitolo, Umberto
Giurescu, Marius
Mappa, Silvia
Grunert, Julia
Childs, Barrett H.
Morschhauser, Franck
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →